401 related articles for article (PubMed ID: 18688917)
1. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
Parke FA; Reveille JD
Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
4. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.
Cavazzana I; Ceribelli A; Cattaneo R; Franceschini F
Autoimmun Rev; 2008 Dec; 8(2):104-6. PubMed ID: 19014870
[TBL] [Abstract][Full Text] [Related]
5. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
Cansu DU; Kalifoglu T; Korkmaz C
J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
[TBL] [Abstract][Full Text] [Related]
6. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
7. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
10. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
[TBL] [Abstract][Full Text] [Related]
11. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
12. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.
Marotte H; Fontanges E; Bailly F; Zoulim F; Trepo C; Miossec P
Rheumatology (Oxford); 2007 Jan; 46(1):97-9. PubMed ID: 16720634
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
[TBL] [Abstract][Full Text] [Related]
14. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
15. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
17. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
[TBL] [Abstract][Full Text] [Related]
18. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
20. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.
Iannone F; La Montagna G; Bagnato G; Gremese E; Giardina A; Lapadula G
J Rheumatol; 2014 Feb; 41(2):286-92. PubMed ID: 24429167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
